Dr. John Sosa, a double board-certified expert in family and lifestyle medicine and the Chief Medical Officer for Drip Health ...
WALTHAM, Mass., November 01, 2024--Global Partners LP (NYSE:GLP) ("Global" or the "Partnership") announced today that it has successfully completed the acquisition of a liquid energy terminal in ...
The company benefits from GLP-1 drug sales and is positioned for ... and individual investors who may not be licensed or certified by any institute or regulatory body.
It found that over 12 months, 1.4% of adolescents on GLP-1 drugs had a suicide attempt or ideation, compared with 2.3% who weren’t on the medicines. There was no sign of an increase associated ...
But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...
Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug problems? Striking new data suggests they might. On Thursday, the journal ...
Among the findings, the report published Monday highlights the impact of Ozempic, other GLP-1 drugs and hormones used in gender-affirming care and lays out sex- and gender-specific risks of stroke.
Expanding access to obesity medications would significantly lower mortality rates, particularly in high-obesity states, saving over 50,000 lives yearly and improving health equity across the ...
along with researchers from CBSET (Center for Biomedical Science and Engineering Technology)—a GLP-certified research facility that conducted preclinical large-animal studies for FDA submission ...
One of the founders of DeepQure, Professor Chang Wook Jeong, from Seoul National University Hospital, along with researchers from CBSET (Center for Biomedical Science and Engineering Technology)-a GLP ...
When GLP-1 medications were first introduced for ... of Obesity Medicine website and search for a physician who is board certified. That doesn't mean your primary care doctor is not the right ...